Week In Review: China's Innovent And Lilly Form $456 Million Cancer Biologics Alliance

Innovent Biologics, a four-year-old Suzhou biopharma, announced a very broad ten-year cross-border collaboration with Eli Lilly (NYSE: LLY) that includes as many as six potential biologic cancer treatments.